
TLX Stock Forecast & Price Target
TLX Analyst Ratings
Bulls say
Telix Pharmaceuticals is poised for success due to its development of radiopharmaceuticals for cancer management, with its current primary revenue source being the US sales of Illuccix for prostate cancer imaging. The company utilizes a DCF valuation methodology with a probability of approval for its various programs and a sum-of-parts valuation, resulting in a total market value of $6.66B and a 12-month price objective of $20 per share. Risks include clinical and regulatory failures, delays in advancing pipelines, and competitive risks, but we reiterate our OUTPERFORM rating and maintain a $22 PT.
Bears say
Telix Pharmaceuticals is facing a negative outlook as the company largely relies on one product, Illuccix, for its revenue and has a limited current pipeline. Additionally, their main revenue source, Illuccix, is primarily used as an imaging agent and not for treating tumors, which may limit potential for future growth. The company's valuation also raises concerns, as its sum-of-parts valuation relies on a high multiple and discounted back earnings.
This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
TLX Analyst Forecast & Price Prediction
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares